Last reviewed · How we verify

Rosuvastatin and Ezetimibe

Hanmi Pharmaceutical Company Limited · FDA-approved active Small molecule

Rosuvastatin and Ezetimibe is a Statin and ezetimibe combination Small molecule drug developed by Hanmi Pharmaceutical Company Limited. It is currently FDA-approved for Hypercholesterolemia and dyslipidemia, Cardiovascular risk reduction in patients requiring additional LDL-C lowering. Also known as: Crestor and Ezetrol.

Rosuvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action.

Rosuvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action. Used for Hypercholesterolemia and dyslipidemia, Cardiovascular risk reduction in patients requiring additional LDL-C lowering.

At a glance

Generic nameRosuvastatin and Ezetimibe
Also known asCrestor and Ezetrol
SponsorHanmi Pharmaceutical Company Limited
Drug classStatin and ezetimibe combination
TargetHMG-CoA reductase and NPC1L1 transporter
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Rosuvastatin is a statin that reduces cholesterol synthesis in the liver by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol production. Ezetimibe selectively inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter. Together, they provide complementary mechanisms to reduce both endogenous cholesterol production and dietary cholesterol uptake, resulting in greater LDL-C lowering than either agent alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rosuvastatin and Ezetimibe

What is Rosuvastatin and Ezetimibe?

Rosuvastatin and Ezetimibe is a Statin and ezetimibe combination drug developed by Hanmi Pharmaceutical Company Limited, indicated for Hypercholesterolemia and dyslipidemia, Cardiovascular risk reduction in patients requiring additional LDL-C lowering.

How does Rosuvastatin and Ezetimibe work?

Rosuvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action.

What is Rosuvastatin and Ezetimibe used for?

Rosuvastatin and Ezetimibe is indicated for Hypercholesterolemia and dyslipidemia, Cardiovascular risk reduction in patients requiring additional LDL-C lowering.

Who makes Rosuvastatin and Ezetimibe?

Rosuvastatin and Ezetimibe is developed and marketed by Hanmi Pharmaceutical Company Limited (see full Hanmi Pharmaceutical Company Limited pipeline at /company/hanmi-pharmaceutical-company-limited).

Is Rosuvastatin and Ezetimibe also known as anything else?

Rosuvastatin and Ezetimibe is also known as Crestor and Ezetrol.

What drug class is Rosuvastatin and Ezetimibe in?

Rosuvastatin and Ezetimibe belongs to the Statin and ezetimibe combination class. See all Statin and ezetimibe combination drugs at /class/statin-and-ezetimibe-combination.

What development phase is Rosuvastatin and Ezetimibe in?

Rosuvastatin and Ezetimibe is FDA-approved (marketed).

What are the side effects of Rosuvastatin and Ezetimibe?

Common side effects of Rosuvastatin and Ezetimibe include Myalgia, Elevated liver enzymes, Headache, Gastrointestinal disturbance.

What does Rosuvastatin and Ezetimibe target?

Rosuvastatin and Ezetimibe targets HMG-CoA reductase and NPC1L1 transporter and is a Statin and ezetimibe combination.

Related